Recognition Versus Adaptive Up-regulation and Degradation of CC Chemokines by the Chemokine Decoy Receptor D6 Are Determined by Their N-terminal Sequence*

The chemokine decoy receptor D6 controls inflammatory responses by selective recognition and degradation of most CCR1 to CCR5 agonistic ligands. CCL14 is a homeostatic chemokine present at high concentrations in the serum with a weak agonist activity on CCR1. Under inflammatory conditions, plasmin and UPA-mediated truncation of 8 amino acids generates the potent CCR1/CCR3/CCR5 isoform CCL14(9–74), which is further processed and inactivated by dipeptidyl peptidase IV/CD26 that generates CCL14(11–74). Here we report that D6 efficiently binds both CCL14 and its truncated isoforms. Like other D6 ligands, the biologically active CCL14(9–74) induces adaptive up-regulation of D6 expression on the cell membrane and is rapidly and efficiently degraded. In contrast, the D6-mediated degradation of the biologically inactive isoforms CCL14(1–74) and CCL14(11–74) is very inefficient. Thus, D6 cooperates with CD26 in the negative regulation of CCL14 by the selective degradation of its biologically active isoform. Analysis of a panel of CC chemokines and their truncated isoforms revealed that D6-mediated chemokine degradation does not correlate with binding affinity. Conversely, degradation efficiency is positively correlated with D6 adaptive up-regulation. Sequence analysis indicated that a proline residue in position 2 of D6 ligands is dispensable for binding but crucial for D6 adaptive up-regulation and efficient degradation.

[1]  G. Opdenakker,et al.  Synergistic up‐regulation of MCP‐2/CCL8 activity is counteracted by chemokine cleavage, limiting its inflammatory and anti‐tumoral effects , 2009, European journal of immunology.

[2]  P. Proost,et al.  Regulation of chemokine activity by posttranslational modification. , 2008, Pharmacology & therapeutics.

[3]  A. Mantovani,et al.  Role of the chemokine decoy receptor D6 in balancing inflammation, immune activation, and antimicrobial resistance in Mycobacterium tuberculosis infection , 2008, The Journal of experimental medicine.

[4]  G. Opdenakker,et al.  Citrullination of CXCL8 by peptidylarginine deiminase alters receptor usage, prevents proteolysis, and dampens tissue inflammation , 2008, The Journal of experimental medicine.

[5]  T. Schwartz,et al.  Positive Versus Negative Modulation of Different Endogenous Chemokines for CC-chemokine Receptor 1 by Small Molecule Agonists through Allosteric Versus Orthosteric Binding* , 2008, Journal of Biological Chemistry.

[6]  A. Mantovani,et al.  Regulation of D6 chemokine scavenging activity by ligand- and Rab11-dependent surface up-regulation. , 2008, Blood.

[7]  T. Chun,et al.  Structural and functional characterization of CC chemokine CCL14. , 2007, Biochemistry.

[8]  R. Nibbs,et al.  The atypical chemokine receptor D6 suppresses the development of chemically induced skin tumors. , 2007, The Journal of clinical investigation.

[9]  A. Mantovani,et al.  Protection against inflammation- and autoantibody-caused fetal loss by the chemokine decoy receptor D6 , 2007, Proceedings of the National Academy of Sciences.

[10]  P. Proost,et al.  Natural post-translational modifications of chemokines. , 2006, Biochemical Society transactions.

[11]  Alberto Mantovani,et al.  Tuning inflammation and immunity by chemokine sequestration: decoys and more , 2006, Nature Reviews Immunology.

[12]  R. Ransohoff,et al.  The many roles of chemokines and chemokine receptors in inflammation. , 2006, The New England journal of medicine.

[13]  A. Mantovani,et al.  Silent chemoattractant receptors: D6 as a decoy and scavenger receptor for inflammatory CC chemokines. , 2005, Cytokine & growth factor reviews.

[14]  T. Handel,et al.  Interaction of chemokines and glycosaminoglycans: a new twist in the regulation of chemokine function with opportunities for therapeutic intervention. , 2005, Cytokine & growth factor reviews.

[15]  B. Premack,et al.  Proteolytic Activation of Alternative CCR1 Ligands in Inflammation1 , 2005, The Journal of Immunology.

[16]  Alberto Mantovani,et al.  Increased inflammation in mice deficient for the chemokine decoy receptor D6 , 2005, European journal of immunology.

[17]  Antonio Alcami,et al.  The chemokine receptor D6 limits the inflammatory response in vivo , 2005, Nature Immunology.

[18]  M. Walden,et al.  n-Nonanoyl-CC Chemokine Ligand 14, a Potent CC Chemokine Ligand 14 Analogue That Prevents the Recruitment of Eosinophils in Allergic Airway Inflammation1 , 2004, The Journal of Immunology.

[19]  M. Gobbi,et al.  Differential Recognition and Scavenging of Native and Truncated Macrophage-Derived Chemokine (Macrophage-Derived Chemokine/CC Chemokine Ligand 22) by the D6 Decoy Receptor1 , 2004, The Journal of Immunology.

[20]  Marc Parmentier,et al.  The Core Domain of Chemokines Binds CCR5 Extracellular Domains while Their Amino Terminus Interacts with the Transmembrane Helix Bundle* , 2003, The Journal of Biological Chemistry.

[21]  M. Parmentier,et al.  Urokinase Plasminogen Activator and Plasmin Efficiently Convert Hemofiltrate CC Chemokine 1 into Its Active [9–74] Processed Variant1 , 2001, The Journal of Immunology.

[22]  W. Forssmann,et al.  Hemofiltrate CC chemokines with unique biochemical properties: HCC‐1/CCL14a and HCC‐2/CCL15 , 2001, Journal of leukocyte biology.

[23]  D. Kerjaschki,et al.  The beta-chemokine receptor D6 is expressed by lymphatic endothelium and a subset of vascular tumors. , 2001, The American journal of pathology.

[24]  F. Kirchhoff,et al.  Natural Proteolytic Processing of Hemofiltrate Cc Chemokine 1 Generates a Potent Cc Chemokine Receptor (Ccr)1 and Ccr5 Agonist with Anti-HIV Properties , 2000, The Journal of experimental medicine.

[25]  P. Proost,et al.  Cleavage by CD26/dipeptidyl peptidase IV converts the chemokine LD78beta into a most efficient monocyte attractant and CCR1 agonist. , 2000, Blood.

[26]  K. Matsushima,et al.  International union of pharmacology. XXII. Nomenclature for chemokine receptors. , 2000, Pharmacological reviews.

[27]  T. Schwartz,et al.  Potency of ligands correlates with affinity measured against agonist and inverse agonists but not against neutral ligand in constitutively active chemokine receptor. , 2000, Molecular pharmacology.

[28]  J. Mao,et al.  LD78β, A Non-allelic Variant of Human MIP-1α (LD78α), Has Enhanced Receptor Interactions and Potent HIV Suppressive Activity* , 1999, The Journal of Biological Chemistry.

[29]  A. Mantovani,et al.  The chemokine system: redundancy for robust outputs. , 1999, Immunology today.

[30]  P. Murphy,et al.  The CXC Chemokines Growth-regulated Oncogene (GRO) α, GROβ, GROγ, Neutrophil-activating Peptide-2, and Epithelial Cell-derived Neutrophil-activating Peptide-78 Are Potent Agonists for the Type B, but Not the Type A, Human Interleukin-8 Receptor* , 1996, The Journal of Biological Chemistry.

[31]  M. Raida,et al.  HCC-1, a novel chemokine from human plasma , 1996, The Journal of experimental medicine.

[32]  A. Mantovani,et al.  Chemokines and chemokine receptors: an overview. , 2009, Frontiers in bioscience.

[33]  P. Proost,et al.  Regulation of the immune response by the interaction of chemokines and proteases. , 2003, Advances in immunology.